Role of Octreotide in Non Variceal Bleeding
Non-variceal Gastrointestinal Bleeding
About this trial
This is an interventional treatment trial for Non-variceal Gastrointestinal Bleeding
Eligibility Criteria
Inclusion Criteria: The subjects are adults aged ≥18years old admitted to the intensive care unit of the National hepatology and Tropical Medicine Research institute and Alexandria university presenting with acute non-variceal gastrointestinal bleeding Exclusion Criteria: If they have variceal bleeding received active endoscopic treatment (e.g. hemoclips or monopolar coagulation) known hypersensitivity to somatostatin analogue (octreotide) or any of its components pregnancy or breastfeeding active malignancy and use of somatostatin analogue within the past 7 day.
Sites / Locations
- NHTMRIRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
control
study
80-mg bolus of PPI alone (control group= A), followed by continuous intravenous (IV) infusion at 8 mg/h for a total of 72 hours
octreotide adjunctive group, in addition to the pantoprazole (Study group= B) for 72 h, received a 100-μg bolus of octreotide, followed by continuous IV infusion of 50 μg/h for a total of 72 hours